glp 1 drugs and lupus The anti-inflammatory immunological properties of GLP-1 Receptor Agonists glp 1 for lupus Exploring

In 2023, that number was $71.7bn, a 500% increase, according to a report in the medical journal Jama

In our additional analyses of ophthalmologic end points among the treatment group, both the well-matched cohorts (n = 68 424 per group) with a T2D diagnosis less than 10 years vs greater than 10 years after the index event showed similar incidence of diabetic eye disease over a 2-year follow-up (eg, DME: 5127 [7.5%] vs 5185 [7.6%] events

This shortfall adds to the timeline

It enhances insulin secretion from pancreatic -cells, and decreases glucagon release from pancreatic -cells [16]

While we still need more data, I think GLP-1s deserve a place in the conversation for patients with PCOS, insulin resistance, or obesity who are struggling to conceive.

big pharma and large telehealth marketplaces cant build huge margins around it, so you rarely see splashy campaigns